Abbisko Therapeutics declared that the newest results of the Phase Ib study of its CSF-1R inhibitor Pimicotinib (ABSK021) in curing patients with advanced tenosynovial giant cell tumor ("TGCT"), was published at the 2023 American Society of Clinical Oncology ("ASCO") yearly meeting that took place in Chicago, USA from June 2 to June 6, 2023.
Ammax Bio Inc. declared that the European Medicines Agency (EMA) has approved AMB-05X Priority Medicines (PRIME) designation for the cure of tenosynovial giant cell tumor (TGCT). AmMax Bio delivered positive Phase II information for the novel local management of AMB-05X in patients with TGCT at the Connective Tissue Oncology Society meeting in November 2022. The efficiency information across multiple clinical endpoints and a favorable protection profile support the possibility of AMB-05X as a best-in-class treatment for the therapy of TGCT irrespective of surgical reputability.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5449
Published Date: Dec 07, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The increasing cases of tenosynovial giant cell tumor diseases in almost all age groups people will majorly drive the market growth of the tenosynovial giant cell tumor market.
The market size of the tenosynovial giant cell tumor market is expected to get a CAGR of approximately 5% over the forecast period, i.e., 2024-2036.
The major players in the market are Abbisko Therapeutics, Ammax Bio Inc., HUTCHMED, SynOx Therapeutics Limited, Deciphera Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Amgen Inc., Celleron Therapeutics Limited, Takeda Pharmaceutical Company Limited., Daiichi Sankyo Company, Limited., Chugai Pharmaceutical Co., Ltd., CHEPLAPHARM Arzneimittel GmbH, Ono Pharmaceutical Co., Ltd.
The surgical procedure segment is anticipated to reap the largest market size by the end of 2036 and demonstrate substantial growth scopes.
The market in the North American region is expected to have the largest market share by the end of 2036 and provide more business opportunities in the future.